Table 3.

Drug‐drug interactions labelling differences for dolutegravir 80, 81, 82

Comedication	US prescribing information	European summary of product characteristics	Japan prescribing information
Dofelitide	Contraindicated	Contraindicated	Pilsicainide ‐ Cautiona
Carbamazepine	Same recommendation: DTG 50 mg twice daily in INI naïve patients
Oxcarbazepine	Should be avoided	DTG 50 mg twice daily in INI naïve patients	–a
Phenobarbital	Should be avoided	DTG 50 mg twice daily in INI naïve patients	Cautiona
Phenytoin	Should be avoided	DTG 50 mg twice daily in INI naïve patients	Cautiona
St John's Wort	Should be avoided	DTG 50 mg twice daily in INI naïve patients	Cautiona
Rifampicin	Same recommendation: DTG 50 mg twice daily in INI naïve patients
Efavirenz	Same recommendation: DTG 50 mg twice daily in INI naïve patients
Etravirine	Should not be used without ATV/r, DRV/r, or LPV/r	Use 50 mg twice daily without a bPI. Should not be used without bPI in INI‐resistant patients	Use 50 mg twice daily without a bPI. Do not use without either ATV/r, DRV/r, or LPV/r in INI‐resistant patients
Fosamprenavir	DTG 50 mg twice daily in INI naïve patients	No dose adjustment in INI naïve patients or in absence of INI resistance	Do not use in INI‐resistant patients
Cation‐containing antacids	DTG two hours before or six hours after	Antacid two hours after or six hours before	DTG two hours before or six hours after
Iron/calcium supplements	DTG two hours before or six hours after	Antacid two hours after or six hours before	DTG two hours before or six hours after but with food at the same timea
Metformin	Close monitoring; limit total daily dose	Dose adjustment should be considered	Administer with care; reduce dose as necessarya

ATV/r, atazanavir boosted with ritonavir; bPI, boosted protease inhibitor; DRV/r,darunavir boosted with ritonavir; DTG, dolutegravir; INI, integrase inhibitor; LPV/r, lopinavir boosted with ritonavir.

^aJapan label differs from the US prescribing information and the European summary of product characteristics.